OncoMatch/Clinical Trials/NCT07219212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Is NCT07219212 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including JNJ-90301900 and Cisplatin for squamous cell carcinoma of head and neck.
Treatment: JNJ-90301900 · Cisplatin — This global, open-label, single arm, phase 1b study aims to learn more about whether a treatment called JNJ-90301900 is safe and effective when injected directly into tumors, along with standard chemotherapy and radiation therapy, for participants with head and neck squamous cell cancer (HNSCC; a type of solid tumor that begins in outer tissue layer of the mouth \& throat).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: CDKN2A p16 negative (negative)
Disease stage
Required: Stage III, IVA, IVB
Excluded: Stage 0, I, II, IVC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Mayo Clinic · Jacksonville, Florida
- Moffit Cancer center · Tampa, Florida
- Emory University · Atlanta, Georgia
- Montefiore Medical Center · The Bronx, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07219212 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CDKN2A?
Yes, CDKN2A p16 negative is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA or IVB is required.
Is there an age limit?
Yes. Patients must be 74 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages